Oral Fluid CDM Test for Medication Adherence and Interaction Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting medication nonadherence (NA) and drug-drug interactions (DDIs) in patients with chronic conditions, particularly cardiometabolic diseases, are inadequate due to the complexity of polypharmacy, leading to challenges in distinguishing these issues from disease progression, and existing systems lack an effective and standardized approach for clinical decision-making.
Innovation Solution
A chronic disease management (CDM) test that involves obtaining an oral fluid sample to analyze for various drug classes, identifying recently ingested medications, detecting NA or DDIs, and providing tailored treatment plans to address these issues, including adjusting drug dosages or discontinuing medications as necessary.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypharmacologic therapy is used to treat chronic conditions, then treatment effectiveness is improved, but the risk of medication nonadherence and drug-drug interactions increases
Solution Approach 1:
The CDM test performs preliminary detection of medication nonadherence and drug-drug interactions before they lead to clinical deterioration. By analyzing oral fluid samples for the presence of multiple medications and their metabolites, the system proactively identifies adherence issues and potential interactions, allowing clinicians to intervene before harm occurs.
Solution Approach 2:
The CDM test acts as an intermediary diagnostic tool between polypharmacologic therapy and clinical outcomes. It provides objective evidence about medication adherence and potential interactions, bridging the gap between prescribed therapy and actual patient response, enabling more informed clinical decisions.
2Reliability
If multiple medications are prescribed for chronic disease management, then disease control is improved, but distinguishing treatment failures from disease progression becomes more difficult
Solution Approach 1:
The CDM test segments the complex problem of treatment failure analysis into distinct components: it separately detects medication nonadherence through metabolite analysis and identifies drug-drug interactions through presence/absence patterns of multiple medications. This segmentation allows clinicians to systematically evaluate each potential cause rather than facing a undifferentiated clinical picture.
Solution Approach 2:
The CDM test provides feedback information about actual medication intake and potential interactions that complements clinical observations. This feedback loop enables clinicians to distinguish whether poor disease control is due to nonadherence, interactions, or true disease progression, leading to more targeted interventions.
3Ease of operation
If traditional detection methods like self-report or pharmacy data are used to monitor medication adherence, then implementation is simple, but detection accuracy is insufficient
Solution Approach 1:
The CDM test replaces mechanical/reporting-based adherence monitoring methods with a biochemical detection system. Instead of relying on patient self-reporting or pharmacy refill records, the test directly detects medication metabolites in oral fluid, providing objective physiological evidence of actual drug intake and timing.
4Measurement precision
If invasive methods like blood or urine drug measurements are used to detect medication adherence, then detection accuracy is improved, but patient convenience and practicality deteriorate
Solution Approach 1:
The CDM test changes the biological parameter being measured from blood or urine to oral fluid. Oral fluid provides comparable pharmacokinetic information about recent medication intake but is non-invasive, easier to collect, and more acceptable to patients, particularly those with multiple comorbidities who may already undergo frequent invasive testing.
Data Source
AI summary
The present disclosure provides methods for using a chronic disease management (CDM) test to evaluate, diagnose, manage, facilitate, and inform clinical care of patients with chronic conditions, by providing a reliable and convenient diagnostic test for detecting medication nonadherence (NA) and drug-drug interactions (DDIs).